Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by PDT Partners LLC

PDT Partners LLC increased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 7.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 248,607 shares of the company's stock after acquiring an additional 18,130 shares during the quarter. PDT Partners LLC owned about 0.54% of Pacira BioSciences worth $4,684,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Sterling Capital Management LLC lifted its stake in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after buying an additional 1,208 shares during the period. Caitlin John LLC grew its holdings in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after acquiring an additional 1,776 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after buying an additional 513 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares during the period. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Down 0.6 %

PCRX traded down $0.15 on Thursday, reaching $26.75. The company's stock had a trading volume of 585,142 shares, compared to its average volume of 986,078. The stock has a 50 day moving average of $24.58 and a two-hundred day moving average of $21.68. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -13.18 and a beta of 0.71.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PCRX. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Barclays lifted their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 target price on shares of Pacira BioSciences in a research report on Tuesday, April 8th. HC Wainwright lifted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and increased their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $26.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.